Published 2014 | Version v1.0.0

Rituximab in Autoimmune CNS Disease

Abstract

Investigators at University of Sydney, Australia, and 14 international centers assessed the utility and safety of rituximab in 144 children (median age 8 years, range 0.7-17; 103 female) with autoimmune and inflammatory disorders of the CNS.

Files

PNB-2014-28-8-7.pdf

Files (99.9 kB)

Name Size Download all
md5:cb52a58ea1d802f609ebc1651cd110cf
99.9 kB Preview Download

Additional details

Identifiers

Other
PNB-2014-28-8-7

Dates

Created
2014
When the item was originally created.